Biological markers of response for kidney cancer

To date, a reliable biomarker is yet to be discovered for the response of kidney cancer patients to treatment or for prognosis. In this review paper, Dr Robert Motzer and his research group from Memorial Sloan Kettering in the USA identified a set of 26 genes whose activity correlated with progression-free survival in the combination […]

read more

Funding approved for avelumab in combination with axitinib for untreated advanced kidney cancer

KCSN are formal consultants to NICE and part of the process that appraises all new kidney cancer drugs. We are delighted to tell you that, as from today, kidney cancer patients can get NHS funding via the Cancer Drugs Fund for avelumab in combination with axitinib as a first-line treatment for patients with untreated advanced […]

read more

Evaluation of brain metastases in patients with kidney cancer treated with avelumab plus axitinib

In this video interview from Practice Update, Dr Eric Jonasch from MD Anderson Cancer Center in the USA talks about some interesting data on brain metastases in patients who have received a combination therapy. Renal cell carcinoma (RCC) patients will develop brain metastases in about 10% to 20% of the time, and the treatment for […]

read more

ASCO GU 2020: Immunotherapy combinations effective for brain metastases

Two small studies reported on patients whose kidney cancer had spread into the brain at the American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium held in San Francisco last weekend. The first study was a real-world report of 17 patients with advanced kidney cancer in the brain. The patients were treated with ipilimumab and […]

read more

New first-line immunotherapy plus TKI combinations for metastatic kidney cancer

Approval of axitinib plus pembrolizumab and axitinib plus avelumab in the first-line treatment of metastatic renal cell carcinoma (RCC) by both the Food and Drug Administration (FDA) in America and the European Commission represent milestone events for the treatment of metastatic RCC in 2019. Approval of the avelumab plus axitinib combination was based on the […]

read more

Avelumab as a first- or second-line treatment for metastatic kidney cancer

A recent study looked at the efficacy and safety of first- or second-line avelumab (an anti–PD-L1 immunotherapy) in patients with metastatic clear cell renal cell carcinoma (RCC). A total of 62 patients were treated with avelumab in the first-line (intravenous infusion every 2 weeks) and 20 patients were treated with avelumab in the second-line. Most […]

read more

Comparison of first-line immunotherapy combinations for advanced kidney cancer

In this paper, three clinical trials with immunotherapy combinations for the first-line treatment of clear renal cell carcinoma (RCC) are discussed. Dr  Robert Motzer from Memorial Sloan Kettering Cancer Center in New York compared the findings from the three trials at the Annual Chemotherapy Foundation Symposium (CFS) in New York last week. All three phase […]

read more

European Commission approves avelumab plus axitinib combination for the first-line treatment of advanced kidney cancer

Based on the findings from the pivotal phase III JAVELIN Renal 101 study, the European Commission has approved avelumab in combination with axitinib for the first-line treatment of advanced renal cell carcinoma (RCC). JAVELIN Renal 101 demonstrated that avelumab in combination with axitinib significantly lowered risk of disease progression or death by 31% and nearly […]

read more

ESMO 2019: Kidney cancer tumour shrinkage in patients who did not have surgery

This interview with Dr Monty Pal, Associate Professor from the City of Hope National Medical Center in California, USA discusses tumour shrinkage in patients who did not have a nephrectomy. The interview was conducted at the European Society of Medical Oncology (ESMO) 2019 conference in Barcelona earlier this month. Dr Pal discusses the results from […]

read more

ESMO 2019: First-line avelumab plus axitinib in sarcomatoid kidney cancer – results from JAVELIN Renal 101

Results from the JAVELIN Renal 101 study to evaluate avelumab plus axitinib in untreated sarcomatoid renal cell carcinoma (RCC) were presented at the European Society for Medical Oncology (ESMO) conference in Barcelona over the weekend. Sarcomatoid differentiation can occur in all subtypes of renal cell carcinoma (RCC) and is an aggressive form of RCC. JAVELIN […]

read more
Showing 1 to 10 of 26 results
  TOP